000028 国药一致
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)3.7203.6639.5369.5769.257
总资产报酬率 ROA (%)1.3591.3513.5473.4823.245
投入资产回报率 ROIC (%)2.0261.9935.3315.3054.891

边际利润分析
销售毛利率 (%)10.68511.09111.99312.15411.730
营业利润率 (%)2.5180.7713.2693.1402.856
息税前利润/营业总收入 (%)2.7211.0963.5483.4053.200
净利润/营业总收入 (%)1.9370.3192.5952.4122.235

收益指标分析
经营活动净收益/利润总额(%)91.566236.50688.96892.31493.073
价值变动净收益/利润总额(%)14.82738.4248.9717.26914.805
营业外收支净额/利润总额(%)-0.9130.3460.2350.2161.136

偿债能力分析
流动比率 (X)1.4881.5151.4941.5081.423
速动比率 (X)1.1941.2161.1661.1351.083
资产负债率 (%)57.85856.35655.90254.37257.876
带息债务/全部投入资本 (%)40.42939.35838.61734.71338.643
股东权益/带息债务 (%)134.633138.425140.732166.172137.493
股东权益/负债合计 (%)62.16265.93065.48669.59560.275
利息保障倍数 (X)12.0383.40413.09213.19510.294

营运能力分析
应收账款周转天数 (天)105.47690.84276.13672.86378.376
存货周转天数 (天)42.36641.90542.88343.12641.485